

David A Braun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9356737/publications.pdf>

Version: 2024-02-01

44
papers

3,025
citations

236925

25
h-index

330143

37
g-index

46
all docs

46
docs citations

46
times ranked

3623
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. <i>Nature Medicine</i> , 2020, 26, 909-918. | 30.7 | 488 |
| 2 | A large peptidome dataset improves HLA class I epitope prediction across most of the human population. <i>Nature Biotechnology</i> , 2020, 38, 199-209. | 17.5 | 324 |
| 3 | Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 649-661.e5. | 16.8 | 263 |
| 4 | Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 632-648.e8. | 16.8 | 230 |
| 5 | Beyond conventional immune-checkpoint inhibition – novel immunotherapies for renal cell carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 199-214. | 27.6 | 179 |
| 6 | Clinical Validation of <i>PBRM1</i> Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2019, 5, 1631. | 7.1 | 166 |
| 7 | Metabolomic adaptations and correlates of survival to immune checkpoint blockade. <i>Nature Communications</i> , 2019, 10, 4346. | 12.8 | 139 |
| 8 | Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 244-256. | 27.6 | 138 |
| 9 | Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. <i>Journal of Clinical Oncology</i> , 2020, 38, 63-70. | 1.6 | 109 |
| 10 | Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 808. | 12.8 | 84 |
| 11 | irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 2174-2184. | 7.0 | 80 |
| 12 | Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. <i>Nature</i> , 2022, 605, 532-538. | 27.8 | 70 |
| 13 | Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). <i>Journal of Clinical Oncology</i> , 2020, 38, 4240-4248. | 1.6 | 69 |
| 14 | Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2020, 3, 372-381. | 5.4 | 59 |
| 15 | HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. <i>Lancet Oncology</i> , The, 2022, 23, 172-184. | 10.7 | 58 |
| 16 | Acquired mechanisms of immune escape in cancer following immunotherapy. <i>Genome Medicine</i> , 2018, 10, 87. | 8.2 | 51 |
| 17 | <i>CDKN2A</i> Alterations and Response to Immunotherapy in Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 4025-4035. | 7.0 | 51 |
| 18 | PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. <i>Clinical Cancer Research</i> , 2019, 25, 6080-6088. | 7.0 | 50 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. <i>European Journal of Cancer</i> , 2020, 135, 203-210. | 2.8 | 50 |
| 20 | Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1371-1380. | 7.0 | 49 |
| 21 | Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. <i>Cancer Immunology Research</i> , 2020, 8, 1075-1084. | 3.4 | 47 |
| 22 | Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma. <i>Genetics in Medicine</i> , 2020, 22, 1366-1373. | 2.4 | 40 |
| 23 | Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2021, 7, 1815. | 7.1 | 40 |
| 24 | Integrative clinical and molecular characterization of translocation renal cell carcinoma. <i>Cell Reports</i> , 2022, 38, 110190. | 6.4 | 40 |
| 25 | Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). <i>Journal of Clinical Oncology</i> , 2022, 40, 2913-2923. | 1.6 | 40 |
| 26 | Optimized Liquid and Gas Phase Fractionation Increases HLA-Peptidome Coverage for Primary Cell and Tissue Samples. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100133. | 3.8 | 32 |
| 27 | From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. <i>Clinical Cancer Research</i> , 2022, 28, 831-839. | 7.0 | 12 |
| 28 | Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 4045-4055. | 7.0 | 12 |
| 29 | Tumor-Infiltrating T Cells – A Portrait. <i>New England Journal of Medicine</i> , 2022, 386, 992-994. | 27.0 | 10 |
| 30 | Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial. <i>Clinical Cancer Research</i> , 2022, 28, 748-755. | 7.0 | 9 |
| 31 | Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. <i>Cancer Journal (Sudbury, Tj ETQq1 1 0,784314 rgBT /Ove</i> | 2.0 | 8 |
| 32 | State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era. <i>European Urology Focus</i> , 2020, 6, 37-40. | 3.1 | 6 |
| 33 | Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1454-1461. | 4.1 | 6 |
| 34 | Neurotoxicities of novel non-steroidal anti-androgens for prostate cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 166, 103463. | 4.4 | 3 |
| 35 | Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4531-4531. | 1.6 | 3 |
| 36 | A Disturbing Decline. <i>New England Journal of Medicine</i> , 2019, 380, 2257-2262. | 27.0 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experience.. Journal of Clinical Oncology, 2022, 40, 6520-6520. | 1.6 | 1 |
| 38 | OTHR-04. INCIDENCE AND SURVIVAL OUTCOMES IN UROTHELIAL CARCINOMA BRAIN METASTASES. Neuro-Oncology Advances, 2019, 1, i18-i19. | 0.7 | 0 |
| 39 | What was old is new again: learning from the modern master clinician. Clinical Teacher, 2019, 16, 274-276. | 0.8 | 0 |
| 40 | Effect of high-dose corticosteroid use on efficacy of immune checkpoint inhibitors in patients with renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2021, 39, 4583-4583. | 1.6 | 0 |
| 41 | Molecular characterization of the tumor microenvironment in chromophobe renal cell carcinoma (ChRCC) and related oncocytic neoplasms.. Journal of Clinical Oncology, 2022, 40, 4549-4549. | 1.6 | 0 |
| 42 | Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors.. Journal of Clinical Oncology, 2022, 40, 2622-2622. | 1.6 | 0 |
| 43 | Single cell transcriptomic characterization of natural killer (NK) cell populations in clear cell renal cell carcinoma and association with clinical outcomes.. Journal of Clinical Oncology, 2022, 40, e16521-e16521. | 1.6 | 0 |
| 44 | Fumarate hydratase-deficient renal cell carcinoma: The real-world experience at Dana-Farber Cancer Institute and Moores Cancer Center.. Journal of Clinical Oncology, 2022, 40, e16522-e16522. | 1.6 | 0 |